Chlorthalidone in mild hypertension - dose response relationship

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Hypertension Research

Background:

• Mild hypertension requires effective and safe treatment options.
• Understanding the dose-response relationship of antihypertensive medications is crucial for optimizing therapy.
• Chlorthalidone is a commonly prescribed diuretic for hypertension.

Purpose of the Study:

• To determine the dose-response curve of chlorthalidone in patients with untreated mild hypertension.
• To identify the optimal starting dose of chlorthalidone for efficacy and safety.
• To evaluate the incidence of adverse biochemical changes and unwanted effects at different chlorthalidone dosages.

Main Methods:

• A double-blind, multicenter, family practice study involving 134 patients with mild hypertension.
• Patients received chlorthalidone in doses of 25, 50, 75, or 100 mg over an 8-week period.
• Blood pressure, blood urea, serum uric acid, and serum potassium levels were monitored.

Main Results:

• All chlorthalidone doses significantly reduced systolic and diastolic blood pressure by 8 weeks (mean reduction of -18 and -10 mmHg, respectively).
• A flat dose-response curve was observed, with no significant differences in blood pressure reduction among the dosage groups.
• The 25 mg group showed the least adverse changes in blood urea, serum uric acid, and serum potassium, with fewer unwanted effects overall.

Conclusions:

• The optimal starting dose for chlorthalidone in mild to moderate hypertension appears to be 25 mg.
• This lower dose provides significant blood pressure reduction with a better safety profile regarding biochemical and unwanted effects.
• Further research may explore individualized dosing strategies based on patient response and tolerance.